Press release
Envisagenics presents latest case study at Oligonucleotide Therapeutics and Delivery 2020
Oligonucleotide Therapeutics and Delivery
Envisagenics is a spin out of the world-renowned Cold Spring Harbor Laboratory (CSHL) from the laboratory of Dr. Adrian R. Krainer, an expert in the field of splicing. The Krainer laboratory was the first to perform in-vitro splicing studies, identify the regulatory proteins of alternative splicing, discover the involvement of spliceosomal proteins in cancer and genetic diseases and finally prove the efficacy of RNA therapeutics to cure disease with the FDA approval of Spinraza for treatment of Spinal Muscular Atrophy.
Envisagenics will be presenting the latest case study on day one of the conference discussing:
Case study: Discovery and development of RNA-therapeutics for Triple Negative Breast Cancer
o Envisagenics' SpliceCore platform integrates proprietary machine learning algorithms, high performance computing, and RNA-splicing analytics to identify disease-specific alternatively spliced RNA that will function as therapeutic targets
o Discovery of TNBC specific splicing isoforms
o Design and development of RNA-therapeutics targeting TNBC specific splicing isoforms using machine learning
o Functional qualification of SpliceCore designed ASOs
Maria Luisa Pineda, CEO and Co-founder, Envisagenics
Dr. Maria Luisa Pineda is the co-founder and CEO of Envisagenics, Inc. a biotech spinout of Cold Spring Harbor Laboratory that integrates proprietary machine learning algorithms, high performance computing, and RNA-splicing analytics to identify disease-specific splicing variants as therapeutic targets. Envisagenics has leveraged its SpliceCore® software platform for therapeutic development with its first pipeline of assets in triple negative breast cancer.
The event brochure with the full agenda and speaker line-up is available to download: www.oligonucleotide.co.uk/openpr4
Oligonucleotide Therapeutics and Delivery
Main conference: 16th - 17th September 2020
London, UK
For media queries please contact Jinna Sidhu at hsidhu@smi-online.co.uk or call +44 (0)20 7827 6088
India House, 45 Curlew Street
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Envisagenics presents latest case study at Oligonucleotide Therapeutics and Delivery 2020 here
News-ID: 2058343 • Views: …
More Releases from SMi Group
Exclusive Speaker Interview with AOBiome ahead of the 22nd Pain Therapeutics Con …
SMi Reports: Exclusive speaker interview with Todd Krueger at AOBiome released for the Pain Therapeutics Conference
The pain therapeutics industry has grown at an exponential rate in recent years. The 22nd Annual Pain Therapeutics conference will cover the leading advances in pain therapeutics, exploring late development clinical trials, novel treatments for chronic conditions, technology collaboration treatments, using VR and Medical Devices that carry out non-invasive nerve stimulation.
Industry leaders will uncover the…
Exclusive Speaker Interview with Ester Lovsin Barle ahead of the 6th Annual High …
Now in its 6th year, the Highly Potent Active Pharmaceutical Ingredients conference offers you peer-to-peer networking with industry experts including heads and directors of EHS, Occupational Hygiene, Quality Assurance and more. Taking place on 9th and 10th May in London, UK.
With a key focus on expanding your community and exploring the latest developments in the industry at this two-day event, including key regulatory updates, and leading case studies from leading…
FDA Keynote Speaker at SMi's 5th Annual Pharmaceutical Microbiology East Coast C …
SMi Group Reports: Keynote FDA speaker Dr. John Arigo, to present at the 4th Annual Pharmaceutical Microbiology East Coast, taking place in just 3 weeks' time on April 27th and 28th, 2022.
With just three weeks remaining until the highly anticipated conference, SMi Group are delighted to announce a key FDA Speaker joining the 5th Annual Pharmaceutical Microbiology East Coast Conference. This event will take place on April 27th and…
Group Captain (ret'd) Robert Daisley invites you to attend Air Mission Planning …
SMi Group reports: Chairman Group Captain (ret'd) Robert Daisley of the Air Mission Planning and Support Conference cordially invites experts to join the conference in London, UK in one week.
With only one week remaining, SMi Group is delighted to publish an invitation letter for SMi's 13th Annual Air Mission Planning & Support Conference, taking place on the 6th and 7th April 2022 in London, UK from the conference chairman.
The…
More Releases for Envisagenics
AI for Drug Discovery Market Will Hit Big Revenues in Future | Atomwise, Envisag …
The latest study released on the Global AI for Drug Discovery Market by AMA Research evaluates market size, trend, and forecast to 2028. The AI for Drug Discovery market study covers significant research data and proofs to be a handy resource document for managers, analysts, industry experts and other key people to have ready-to-access and self-analyzed study to help understand market trends, growth drivers, opportunities and upcoming challenges and about…
Exclusive Speaker Interview with Martin Akerman, Envisagenics Released ahead of …
SMi Group reports: CTO and Co-Founder of Envisagenics, Martin Akerman discusses the challenges and developments in the RNA industry
SMi’s 13th Annual RNA Therapeutics Conference will welcome expert speakers from big pharma companies to bring together cutting-edge discussions in the developments and challenges in the RNA Therapeutics field. The conference will take place on 9th and 10th February 2022 in London UK – live and in person.
The RNA therapeutics industry has…
AI for Drug Discovery Market Insights to 2027 | Atomwise, Insilico Medicine, Num …
The AI for drug discovery market is expected to grow during the forecast period due to the increasing number of cross-industry partnerships & collaborations, a significant growth in venture capital investments, rise in importance of drug discovery and increase in funding of the R&D activities for the use of AI technology in the field of drug discovery. However, limited awareness, unwillingness among medical practitioners to adopt AI-based technologies, unclear regulatory…
AI for Drug Discovery Market Size, Strategy, Business Outlook to 2027 - Atomwise …
Drug discovery is the preliminary step in the process of a novel drug identification and its therapeutic target. Artificial intelligence (AI) is commonly used in the healthcare industry for drug discovery. Artificial intelligence technology has the ability to recognize drug targets, and play a significant role in drug design, discovery, identification and screening of molecules instantly and effectively. Drug discovery or new drug target are being estimated based on potency,…
AI for Drug Discovery Market Growth Strategies 2027 - Lead by Insilico Medicine, …
Global AI for Drug Discovery Market Analysis 2019 to 2027 - is a specialized and in-depth study of the healthcare IT industry with a special focus on the global market trend analysis. The report aims to provide an overview of enteral feeding formulas market with detailed market segmentation by drug type, technology, application, end user and geography. The global AI for drug discovery market is expected to witness high growth…
Artificial intelligence (AI) for Drug Discovery Market Outlook to 2027 by Global …
Drug discovery is the preliminary step in the process of a novel drug identification and its therapeutic target. Artificial intelligence (AI) is commonly used in the healthcare industry for drug discovery. Artificial intelligence technology has the ability to recognize drug targets, and play a significant role in drug design, discovery, identification and screening of molecules instantly and effectively. Drug discovery or new drug target are being estimated based on potency,…
